1 / 21

Redefining the treatment of gastric cancer with Xeloda

Redefining the treatment of gastric cancer with Xeloda. Sheela Rao The Royal Marsden Hospital, London and Surrey, UK. Korean 1. (n=44). 1 250mg/m 2 twice daily d1–14 q3w. Mexican 2. (n=18). Japanese 3. (n=55). 825mg/m 2 twice daily d1–21 q4w. Japanese 4. (n=32).

colleen-liddane
Download Presentation

Redefining the treatment of gastric cancer with Xeloda

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Redefining the treatment of gastric cancer with Xeloda Sheela Rao The Royal Marsden Hospital,London and Surrey, UK

  2. Korean1 (n=44) 1250mg/m2 twice dailyd1–14 q3w Mexican2 (n=18) Japanese3 (n=55) 825mg/m2 twice daily d1–21 q4w Japanese4 (n=32) Xeloda monotherapy: effective and well tolerated in advanced gastric cancer (AGC) Response rate (%) Grade 3/4 AEs (≥5%) Xeloda regimen 34 HFS (9%) 25 HFS (5%) 26 HFS (13%) 19 Hyperbilirubinaemia (6%) 1. Hong YS et al. Ann Oncol 2004;15:134472. Leon-Rodriguez E et al. Ann Oncol 2002;13(Suppl. 5):191 (Abst 708)3. Sakamoto J et al. Anticancer Drugs 2006;17:2316 4. Koizumi W et al. Oncology 2003;64:2326

  3. Phase III study: XP vs FPXeloda + cisplatin vs 5-FU + cisplatin RANDO MIS ATION XP Xeloda1000mg/m2 bid d114 q3w Cisplatin 80mg/m2 3-hour i.v. infusion n=156 Advanced and/ormetastatic gastric cancer n=316 FP 5-FU c.i. 800mg/m2 d15 q3w Cisplatin 80mg/m2 3-hour i.v. infusion n=160 • Primary end-point: non-inferiority in PFS Kang Y et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4018)

  4. XP vs FP: non-inferior PFS Estimated probability 1.0 Median PFSmonths (95% CI) 5.6 (4.9–7.3) 5.0 (4.2–6.3) 0.8 XP (n=139) FP (n=137) 0.6 HR=0.81 (95% CI: 0.63–1.04) Compared to HR upper limit 1.25,p=0.0008 0.4 0.2 0.0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Months Per-protocol analysis Kang Y et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4018)

  5. XP vs FP: trend to superior PFS Estimated probability 1.0 Median PFSmonths (95% CI) 5.6 (4.8–6.9) 5.0 (3.9–5.7) 0.8 XP (n=160) FP (n=156) 0.6 HR=0.80 (95% CI: 0.63–1.03)Test for superiorityp=0.0801 0.4 0.2 0.0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Months Intent-to-treat analysis Kang Y et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4018)

  6. Superior response rate with XP vs FP Kang Y et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4018)

  7. XP (n=156) FP (n=155) Comparable AEs with XP vs FP Common (≥3%) grade 3/4 AEs Patients (%) 40 30 20 10 0 HFS Nausea Anaemia Vomiting Diarrhoea Stomatitis Leucopenia Neutropenia Kang Y et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4018)

  8. XP efficacy similar in German study 1. Moehler M et al. Proc Am Soc Clin Oncol 2006 (Abst 4032) 2. Kang Y et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4018)

  9. REAL-2: Xeloda vs 5-FU and oxaliplatin vs cisplatin • Primary end-point: overall survival • 2x2 design with ECF as standard arm RANDO MIS ATION Epirubicin Cisplatin Xeloda n=250 Epirubicin OxaliplatinXeloda Advanced oesophagogastriccancer n=1002 n=244 Epirubicin Cisplatin Fluorouracil n=263 Epirubicin Oxaliplatin Fluorouracil n=245 1. Sumpter K et al. Br J Cancer 2005;92:197683 2. Cunningham D et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4017)

  10. REAL-2: primary end-point met non-inferior overall survival, Xeloda vs 5-FU Estimated probability 1.0 0.8 0.6 HR=0.86 (95% CI: 0.80–0.99)Compared with HR upper limit 1.23, p<0.0001 0.4 0.2 0.0 0 12 24 36 60 72 48 Months Per-protocol analysis Cunningham D et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4017)

  11. REAL-2:superior overall survival with EOX vs ECF Estimated probability Overall survival(months) 11.2 9.9 1.0 EOX ECF 0.8 0.6 HR=0.80 (95% CI: 0.66–0.97), p=0.020 0.4 0.2 0.0 0 6 12 18 30 36 24 Months Intent-to-treat analysis Cunningham D et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4017)

  12. REAL-2: good safety profiles with Xeloda-based regimens Cunningham D et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4017)

  13. REAL-2: good safety profiles with Xeloda-based regimens Cunningham D et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4017)

  14. REAL-2: good safety profiles with Xeloda-based regimens Cunningham D et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4017)

  15. REAL-2: good safety profiles with Xeloda-based regimens Cunningham D et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4017)

  16. REAL-2: good safety profiles with Xeloda-based regimens Cunningham D et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4017)

  17. REAL-2: good safety profiles with Xeloda-based regimens Cunningham D et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4017)

  18. Docetaxel/Xeloda/cisplatin (DXP): active in first-line AGC Phase III Phase II 1. Moiseyenko V et al. Proc Am Soc Clin Oncol 2005 (Abst 4002)2. Kang Y-K et al. Proc Am Soc Clin Oncol2004 (Abst 4066)

  19. Grade 3/4 AEs: potentially less haematological toxicity with Xeloda Patients (%) 100 TCF (n=221) Phase III 80 DXP (n=40) Phase II 60 40 20 0 HFS Febrileneutropenia Platelets Anaemia Lethargy Vomiting Neuropathy Neutropenia 1. Moiseyenko V et al. Proc Am Soc Clin Oncol 2005 (Abst 4002)2. Kang Y-K et al. Proc Am Soc Clin Oncol2004 (Abst 4066)

  20. Progress so far: overall survivalwith first-line AGC regimens 1997 BSC1 FAMTX1,2 FP1,3,4,6 ECF2,6/EOF7 MCF5/IF3/TCF4 XP6/ECX/EOX7 2006 4 6 8 10 12 Months 1. Vanhoefer U et al. J Clin Oncol 2000;18:2648–57; 2. Waters JS et al. Br J Cancer 1999;80:269–72; 3. Dank M et al. Proc Am Soc Clin Oncol. 2005 (Abst 4003); 4. Moiseyenko V et al. Proc Am Soc Clin Oncol 2005 (Abst 4002) 5. Ross P et al. J Clin Oncol 2002;20:1996–2004; 6. Data on file F Hoffmann La-Roche 7. Cunningham D et al. Proc Am Soc Clin Oncol 2006 (Abst LBA4017)

  21. Xeloda: a highly effective, safe and convenient oral therapy for gastric cancer • Effective and simple with: • cisplatin • oxaliplatin • docetaxel • paclitaxel • triple combinations • Similar safety and efficacy profile to infusional 5-FU • Extensive phase III programme is evaluating Xeloda in: • adjuvant therapy • advanced/metastatic disease

More Related